Practical Considerations for Monoclonal Antibodies in Multiple Myeloma

Dr. Joseph Mikhael, Chief Medical Officer at the International Myeloma Foundation, highlights an ASCO 2018 session about monoclonal antibodies used to treat multiple myeloma. Dr. Mikhael comments on the following:

  • The use of monoclonal antibodies are significant for myeloma patients at first relapse.

  • Monoclonal antibodies may be used in combination with lenalidomide, bortezomib, and other agents to help a patient reach remission.

  • Treatment with monoclonal antibodies must be individualized due to myeloma’s complexities.

In addition, Dr. Mikhael previews the use of new monoclonal antibodies and other new treatments, including CAR T-cell therapy.